USA flag logo/image

An Official Website of the United States Government

Generation of Human Hepatocytes

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71568
Program Year/Program:
2004 / STTR
Agency Tracking Number:
DK067786
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
IN VIVO TECHNOLOGIES
IN VIVO TECHNOLOGIES 1121 FOREST ST RENO, NV 89509
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Generation of Human Hepatocytes
Agency: HHS
Contract: 1R41DK067786-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of this project is to produce "humanized" livers in large animal models such as sheep and pigs that can serve as a reliable source of significant numbers of functional human hepatocytes. The isolated human hepatocytes and/or "humanized" livers can be used for drug toxicity studies as well as for possible clinical use in patients with liver failure. Transplantation of human bone marrow (BM) CD34+ cells from normal donors of diverse genetic background into pre-immune fetal sheep/pigs can be used to generate human liver cells for use in drug toxicity studies (the aim of the present application), and from specific patients to produce livers and/or cells autologous to the patient (future goal requiring proof-of-principle studies). Feasibility data is presented demonstrating that the transplantation of CD34+ cells from human BM, mobilized peripheral blood, and cord blood into this non-injury pre-immune fetal sheep model resulted in the robust formation of relatively large numbers of human liver cells that synthesize and secret human albumin into circulation. In this human/sheep xenograft model donor (human) hepatopoiesis persists long-term (> 2years) without apparent loss of number or function. In the phase I effort we propose to determine: 1) the optimal gestational age of the sheep fetus, and 2) the optimal concentration of human bone marrow CD34+ cells for obtaining the highest percentages of human hepatocytes. Phase II effort will focus on efficient isolation, characterization, and maintenance of human liver cells from the "humanized" liver.

Principal Investigator:

Esmail D. Zanjani
7753281232
ZANJANI@SCS.UNR.EDU

Business Contact:


7753225889
Small Business Information at Submission:

IN VIVO TECHNOLOGIES
IN VIVO TECHNOLOGIES 1121 FOREST ST RENO, NV 89509

EIN/Tax ID: 880353743
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
SIERRA BIOMEDICAL RESEARCH CORPORATION
SIERRA BIOMEDICAL RESEARCH CORP
RENO, NV 89502
RI Type: Domestic nonprofit research organization